The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-018-05102-x.pdf
Reference69 articles.
1. US Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. Updated July 3 (2018) https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm . Accessed 9 July 2018
2. Jeong W, Doroshow JH, Kummar S (2013) United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer 37(3):110–144. https://doi.org/10.1016/j.currproblcancer.2013.06.001
3. Amitay-Laish I, Stemmer SM, Lacouture ME (2011) Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 24(4):386–395. https://doi.org/10.1111/j.1529-8019.2011.01431.x
4. Bowen JM (2013) Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 7(2):162–167. https://doi.org/10.1097/SPC.0b013e32835ec861
5. Gilotrif [package insert] (2016) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs;PLOS ONE;2024-01-24
2. Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib;Drug Design, Development and Therapy;2023-11
3. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis;Drugs;2023-10-26
4. Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study;Breast Care;2023-10-05
5. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer;Clinical Breast Cancer;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3